Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715428 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1ANPC1RAB9A | |
| SCHEMBL19382614 | 0.79 | CYP1A2 (0.61) | CYP1A2CYP2A6MTNR1AHTR2ACYP17A1 | |
| SCHEMBL12912586 | 0.78 | CYP17A1 (0.51) | CYP1A2CYP2A6MTNR1AHTR2ACYP17A1 | |
| SCHEMBL4203130 | 0.78 | CYP1A2 (0.59) | CYP1A2CYP2A6MTNR1AHTR2AMTNR1B | |
| SCHEMBL443625 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2A6MTNR1AHTR2ARAB9A | |
| SCHEMBL30088510 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2A6MTNR1AHTR2ARAB9A | |
| SCHEMBL10866515 | 0.78 | CYP2A6 (0.68) | CYP1A2CYP2A6MTNR1AHTR2ACYP17A1 | |
| SCHEMBL27758533 | 0.78 | MTNR1A (0.51) | MTNR1AMTNR1B | |
| SCHEMBL1402499 | 0.77 | MTNR1A (0.55) | CYP1A2CYP2A6MTNR1AHTR2ANQO2 | |
| SCHEMBL5781073 | 0.77 | CYP1A2 (0.55) | CYP1A2CYP2A6MTNR1AHTR2AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102675056-A | Method for preparing 6-bromo-8-fluoro-2-naphthol | CGENE TECH SUZHOU CHINA CO LTD | 2012-09-19 | — | — | CN | claimed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-102675056-A | Method for preparing 6-bromo-8-fluoro-2-naphthol | CGENE TECH SUZHOU CHINA CO LTD | 2012-09-19 | — | — | CN | disclosed |
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | MEWSHAW RICHARD E (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
| US-4243682-A | ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; ANALGESICS; RHEUMATIC DISEASES | BEECHAM GROUP LIMITED (GB) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | CYP1A2 342/4885CYP2A6 139/4885MTNR1A 38/4885 |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | CYP1A2 342/4885CYP2A6 139/4885MTNR1A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.